StockNews.AI
HIMS
StockNews.AI
53 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Hims & Hers Health, Inc. - HIMS

1. Pomerantz LLP investigates potential securities fraud by Hims & Hers executives. 2. Novo Nordisk ended partnership with Hims & Hers over regulatory compliance issues. 3. Hims & Hers stock dropped 34.63% following the news on June 23, 2025. 4. Concerns raised on patient safety due to mass sale of compounded drugs. 5. Investors may join class action related to this investigation.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The stock's significant drop indicates severe market loss of confidence following fraud allegations. Historically, companies facing similar probes often see prolonged downturns until resolution.

How important is it?

The allegations of fraud and stock price plunge are critical for Hims' investor sentiment and compliance status. Law firm investigations often lead to serious revisiting of business practices, impacting stock performance.

Why Short Term?

Immediate sentiment is affected by the news, but long-term impacts depend on resolution and corrective actions. Companies in similar situations often stabilize once legal matters are clarified.

Related Companies

NVDAAMGN
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Hims & Hers Health, Inc.  ("Hims & Hers" or the "Company") (NYSE: HIMS).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.   The investigation concerns whether Hims & Hers and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On June 23, 2025, Novo Nordisk announced that it would discontinue its partnership with Hims & Hers, ending direct access to its Wegovy weight loss drug through NovoCare Pharmacy.  Novo Nordisk said that Hims & Hers had not complied with legal regulations prohibiting the mass sale of compounded drugs under the misleading notion of "personalization", raising concerns about patient safety.  On this news, Hims & Hers' stock price fell $22.24 per share, or 34.63%, to close at $41.98 per share on June 23, 2025. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com. Attorney advertising.  Prior results do not guarantee similar outcomes.   CONTACT:Danielle PeytonPomerantz LLP[email protected]646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News